BioMerieux (STU:EYWN) Net Interest Margin (Bank Only) %


STU:EYWN BioMerieux SA STU:EYWN
66 GF Score
Price €70.25
GF Value €109.52
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:EYWN
66GF Score
BioMerieux SA STU:EYWN
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioMerieux (STU:EYWN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of €70.25 is trading 35.9% below its estimated GF Value™ of €109.52. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for STU:EYWN:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €109.52 vs. price of €70.25 (35.9% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the STU:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
66GF Score

Get the complete analysis for STU:EYWN

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.25
Price
€109.52
GF Value